Osteoporosis and cardiovascular disease - Brittle bones and boned arteries, is there a link?

被引:239
作者
McFarlane, SI
Muniyappa, R
Shin, JJ
Bahtiyar, G
Sowers, JR
机构
[1] Suny Downstate Med Ctr, Dept Endocrinol, Dept Internal Med, Brooklyn, NY 11203 USA
[2] Kings County Hosp Ctr, Brooklyn, NY USA
[3] Univ Missouri, Columbia, MO 65211 USA
[4] HS Truman Veterans Affairs Med Ctr, Columbia, MO USA
关键词
osteoporosis; cardiovascular disease; aging; atherosclerosis; bone mineral density; risk factors;
D O I
10.1385/ENDO:23:1:01
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Both osteoporosis and cardiovascular disease (CVD) are major public health problems leading to increased morbidity and mortality. Although traditionally viewed as separate disease entities that increase in prevalence with aging, accumulating evidence indicates that there are similar pathophysiological mechanisms underlying both diseases. In addition to menopause and advanced age, other risk factors for CVD such as dyslipidemia, oxidative stress, inflammation, hyperhomocystinemia, hypertension, and diabetes have also been associated with increased risk of low bone mineral density (LBMD). Elevated LDL and low HDL cholesterol are associated with LBMD, altered lipid metabolism is associated with both bone remodeling and the atherosclerotic process, which might explain, in part, the co-existence of osteoporosis and atherosclerosis in patients with dyslipidemia. Similarly, inflammation plays a pivotal role in both atherosclerosis and osteoporosis. Elevated plasma homocysteine levels are associated with both CVD and osteoporosis. Nitric oxide (NO), in addition to its known atheroprotective effects, appears to also play a role in osteoblast function and bone turnover. Supporting this notion, in a small randomized controlled trial, nitroglycerine (an NO donor) was found to be as effective as estrogen in preventing bone loss in women with surgical menopause. Statins, agents that reduce atherogenesis, also stimulate bone formation. Furthermore, bisphosphonates, used in the treatment of osteoporosis, have been shown to inhibit atherogenesis. Intravenous bisphosphonate therapy significantly decreases serum LDL and increases HDL in postmenopausal women. The exciting possibilities of newer pharmacological agents that effectively treat both osteoporosis and CVD hold considerable promise. However, it is important to emphasize that the current evidence linking both of these diseases is far from conclusive. Therefore, additional research is necessary to further characterize the relationship between these two common illnesses.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 116 条
  • [41] Jackson B, 2000, ARZNEIMITTEL-FORSCH, V50, pE380
  • [42] POTENTIATION OF OSTEOCLAST BONE-RESORPTION ACTIVITY BY INHIBITION OF NITRIC-OXIDE SYNTHASE
    KASTEN, TP
    COLLINOSDOBY, P
    PATEL, N
    OSDOBY, P
    KRUKOWSKI, M
    MISKO, TP
    SETTLE, SL
    CURRIE, MG
    NICKOLS, GA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) : 3569 - 3573
  • [43] Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology
    Kemink, SAG
    Hermus, ARMM
    Swinkels, LMJW
    Lutterman, JA
    Smals, AGH
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2000, 23 (05) : 295 - 303
  • [44] Minireview: The OPG/RANKL/RANK system
    Khosla, S
    [J]. ENDOCRINOLOGY, 2001, 142 (12) : 5050 - 5055
  • [45] Nitric oxide response to shear stress by human bone cell cultures is endothelial nitric oxide synthase dependent
    Klein-Nulend, J
    Helfrich, MH
    Sterck, JGH
    MacPherson, H
    Joldersma, M
    Ralston, SH
    Semeins, CM
    Burger, EH
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 250 (01) : 108 - 114
  • [46] Lifestyle factors are associated with osteoporosis in lean women but not in normal and overweight women:: a population-based cohort study of 1222 women
    Korpelainen, R
    Korpelainen, J
    Heikkinen, J
    Väänänen, K
    Keinänen-Kiukaanniemi, S
    [J]. OSTEOPOROSIS INTERNATIONAL, 2003, 14 (01) : 34 - 43
  • [47] Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes
    Koshiyama, H
    Nakamura, Y
    Tanaka, S
    Minamikawa, J
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (08) : 2793 - 2796
  • [48] ATHEROSCLEROSIS - PREVENTION BY AGENTS NOT AFFECTING ABNORMAL LEVELS OF BLOOD-LIPIDS
    KRAMSCH, DM
    ASPEN, AJ
    ROZLER, LJ
    [J]. SCIENCE, 1981, 213 (4515) : 1511 - 1512
  • [49] Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
    Lacey, DL
    Timms, E
    Tan, HL
    Kelley, MJ
    Dunstan, CR
    Burgess, T
    Elliott, R
    Colombero, A
    Elliott, G
    Scully, S
    Hsu, H
    Sullivan, J
    Hawkins, N
    Davy, E
    Capparelli, C
    Eli, A
    Qian, YX
    Kaufman, S
    Sarosi, I
    Shalhoub, V
    Senaldi, G
    Guo, J
    Delaney, J
    Boyle, WJ
    [J]. CELL, 1998, 93 (02) : 165 - 176
  • [50] Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis
    Lane, NE
    Sanchez, S
    Genant, HK
    Jenkins, DK
    Arnaud, CD
    [J]. OSTEOPOROSIS INTERNATIONAL, 2000, 11 (05) : 434 - 442